Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
This report provides updated 4-year efficacy, initial overall survival, and late-emergent safety results. Patients aged 15 years or older with resected stage IIIB–C or IV melanoma were randomly assigned (1:1) to receive nivolumab or ipilimumab. 4- year recurrence-free survival was 51% with nvolumac and 76% with ipillumab.
